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The inhibitory immunoreceptor SIRPa is expressed on myeloid and neuronal cells and
interacts with the broadly expressed CD47. CD47-SIRPa interactions form an innate
immune checkpoint and its targeting has shown promising results in cancer patients.
Here, we report expression of SIRPa on B1 lymphocytes, a subpopulation of murine B
cells responsible for the production of natural antibodies. Mice defective in SIRPa
signaling (SIRPaDCYT mice) displayed an enhanced CD11b/CD18 integrin-dependent
B1 cell migration from the peritoneal cavity to the spleen, local B1 cell accumulation, and
enhanced circulating natural antibody levels, which was further amplified upon
immunization with T-independent type 2 antigen. As natural antibodies are
atheroprotective, we investigated the involvement of SIRPa signaling in atherosclerosis
development. Bone marrow (SIRPaDCYT>LDLR−/−) chimaeric mice developed reduced
atherosclerosis accompanied by increased natural antibody production. Collectively, our
data identify SIRPa as a unique B1 cell inhibitory receptor acting to control B1 cell
migration, and imply SIRPa as a potential therapeutic target in atherosclerosis.
Keywords: B1 cells, natural antibodies, atherosclerosis, immune checkpoint, inhibitory receptor, SIRPa, CD47,
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Signal regulatory protein alpha (SIRPa) is an inhibitory
immunoreceptor known to be expressed on myeloid and
neuronal cells. SIRPa interacts with the broadly expressed cell
surface ligand CD47 present on most cells in the body, including
both hematopoietic and non-hematopoietic cells (1). Binding of
CD47 to SIRPa generates intracellular inhibitory signals via
immunoreceptor tyrosine-based inhibitory motifs (ITIM) in the
cytoplasmic tail of SIRPa. Upon phosphorylation the SIRPa ITIM
act to recruit and activate the tyrosine phosphatases SHP-1 and/or
SHP-2, which inhibit tyrosine-phosphorylation-dependent
signaling events and the resultant downstream cellular effector
functions, including, e.g., phagocytosis (1). As such, the CD47-
SIRPa axis forms an important innate immune checkpoint, with
CD47 acting as so-called “don’t-eat-me” signal, which prevents the
engulfment of healthy cells by myeloid cells (2). However, aberrant
cells, such as cancer cells, may also exploit this pathway by (over)
expressing CD47 and thus escaping immune-mediated destruction.
Therapeutic targeting of the CD47-SIRPa checkpoint has been
most intensively explored in the context of cancer. In fact, recent
first in-human studies of agents interfering with this pathway
demonstrate a favorable safety profile and promising therapeutic
potential (3).
Based on their functions, anatomical location and phenotypical
properties B lymphocytes can be divided into conventional B cells,
also known as B2 cells, representing the majority of B cells, and into
a smaller population of unconventional B1 cells. Inmice, B1 cells are
produced in the fetal liver before birth and afterward reside mainly
in the pleural and peritoneal cavities where they are maintained by
self-renewal (4). In addition, small proportions (<1%), but
significant numbers, of these cells can be found in spleen and
bone marrow (4–6). B1 cells residing in body cavities have a limited
capacity to produce natural antibodies. However, after stimulation,
by, e.g., LPS or viral infection, they migrate to the secondary
lymphoid tissues, including the spleen, where they differentiate
into plasma cells forming the major systemic source of natural
antibodies (7, 8). This conditional migration is governed by the
CD11b/CD18 integrin (7, 9). B1 cells that have arrived to the spleen
gradually lose expression of CD11b/CD18 integrin, with hardly
detectable levels after 6 days (9). Peritoneal B1 cells represent about
35%–70% of all CD19+ cells present in the peritoneal cavity and can
be further divided into B1a (CD19+CD11b+CD5+) and B1b
(CD19+CD11b+CD5−) cells (4). Unlike B2 cells, B1 cells in the
spleen constitutively secrete natural antibodies, which are IgM
antibodies commonly targeting, e.g., phospholipid and
polysaccharide antigens, such as phosphorylcholine,
phosphatidylcholine and lipopolysaccharide (4). Notably, a large
part of the natural IgM antibodies is directed against epitopes
created through lipid peroxidation (so called oxidation-specific
epitopes, OSE), expressed amongst others on apoptotic cells and
modified lipoproteins (10). Protective effects of natural antibodies
against oxidized lipids have been well established in atherosclerosis
(11–14), a chronic inflammatory disease characterized by
accumulation of modified (oxidized) lipids in big and medium
sized arteries (15). The atheroprotective capacity of IgM antibodies
is explained by their binding to oxLDL, thereby preventing oxLDLFrontiers in Immunology | www.frontiersin.org 2uptake by macrophages, which as a consequence reduces foam cell
formation and lesion development (11, 16). Additionally, natural
antibodies are produced to promote clearance of apoptotic cells,
which carry the same OSE as oxLDL (14).
It is known that B1 cell responses are restricted by different
inhibitory immunoreceptors expressed on these cells, including,
e.g., CD5 (17), CD22 (18), Fc gamma receptor IIb (FcgRIIb) (19,
20), and Siglec-G (21, 22). CD5 has been strongly linked to
inhibition of BCR signaling, which prevents unwanted self-
reactivity of B1 cells (23). B1 cells from mice lacking Siglec-G
show a dramatic increase in Ca2+ flux upon anti-IgM treatment
(22) and increased natural antibody production (24), also
suggesting a role of Siglec-G in BCR signaling. All these
receptors commonly exhibit their inhibitory functions through
intracellular immunoreceptor tyrosine-based inhibitory motifs
(ITIM), which upon tyrosine phosphorylation recruit and
activate the cytosolic tyrosine phosphatases SHP-1 and/or
SHP-2. In the case of FcgRIIb, the inositol phosphatases SHIP-
1 and/or SHIP-2 play a prominent role as mediators of inhibitory
signaling (25).
Here, we describe another inhibitory receptor, SIRPa, which is
expressed on B1 cells in mice. We demonstrate that, in contrast to
other currently known inhibitory receptors, SIRPa on B1 cells
negatively regulates their migration, B1 cell numbers in the spleen,
and systemic natural antibody production, without directly
affecting B1 cell activation. Mice lacking the cytoplasmic tail of
SIRPa (SIRPaDCYT mice) in their hematopoietic compartment are
protected against atherosclerosis with increased natural antibody
levels against oxidized lipids. This identifies SIRPa as a novel
immunoinhibitory receptor on B1 cells with unique regulatory
functions and potential for therapeutic targeting in atherosclerosis.MATERIALS AND METHODS
Mice
SIRPa−/− mice maintained on a C57BL/6 background have been
described and were maintained in the Institute for Experimental
Animals at Kobe University Graduate School of Medicine under
specific-pathogen free conditions (26). C57BL/6 mice with a
targeted deletion of the SIRPa cytoplasmic region have been
described previously (27, 28). The mice that were originally
generated onto the 129/Sv background were backcrossed onto
C57BL/6 mice for at least 13 generations. Wild-type (wt) C57BL/
6 mice of the same genetic background were maintained under
specific pathogen-free conditions together with the SIRPaDCYTmice
in the breeding facility of The Netherlands Cancer Institute,
Amsterdam, The Netherlands or the VU Medical Center,
Amsterdam, The Netherlands. Unless indicated otherwise
littermates from heterozygous breedings were used for both wild
type and mutant mice. Bone marrow was isolated and used for
transplantation at the animal facility of Maastricht University,
Maastricht, The Netherlands. Animals were housed in ventilated
cages and treated according to European Commission guidelines.
They were euthanized using combination of isofluran and CO2. All
animal experiments were approved by the Animal Welfare
Committee of the VU Medical Center Amsterdam, TheOctober 2020 | Volume 11 | Article 570963
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and The Netherlands Cancer Institute, Amsterdam, The
Netherlands. LDLR−/− mice on C57BL/6J background were
obtained from Jackson Laboratory (Bar Harbor, ME, USA).
Flow Cytometric Analysis of SIRPa
Expression on Mouse B Cells
Mouse B cells were isolated from the peritoneal cavity by
peritoneal lavage of 8–12 weeks old SIRPaDCYT mice and age
matched wt mice. Mice were sacrificed and immediately after
that 5 ml of cold PBS containing 3% of fetal calf serum (FCS) and
3mM EDTA was injected into their peritoneal cavity. After
gentle massage, cells were collected and used for analysis of
SIRPa expression. Additionally, bone marrow and spleens of the
same mice were isolated and blood samples were taken to analyze
for expression of SIRPa. Fetal livers were isolated from mice of
FVB background at E12. Single cell suspensions of splenocytes
were prepared after the spleens were homogenized through
100µm filter (BD Biosciences, Bedford, MA, USA), lysed with
lysis buffer and washed twice with cold PBS. For blood analysis
whole blood was first spun down at 2,000 rpm at 4°C for 10 min
and plasma was collected and stored at −80°C for later analysis of
antibodies level. Erythrocytes were lysed using cold lysis buffer
containing 155mM NH4Cl, 10mM KHCO3, and 0.1mM EDTA
(ethylene diamine tetra acetic acid), pH 7.4. For flow cytometry
analysis first Fc receptors were blocked using a-CD16/CD32
antibody (clone 2.4G2, BD Biosciences, Bedford, MA, USA). The
cells were subsequently washed and stained for following surface
markers with directly conjugated antibodies against CD19/B220
(PerCP Cy5.5 or eFluor 450), CD11b (Alexa Fluor 488), CD5
(PE), IgM (PE), SIRPa (APC or PerCP 710) (all antibodies
purchased from eBioscience, San Diego, CA, USA), and CD43
(APC Cy7, BioLegend, San Diego, CA, USA). Expression of
proteins was measured using FACS Canto II HTS (BD
Biosciences, Bedford, MA, USA) and analyzed using FlowJo
software (FlowJo LLC, Ashland, OR, USA). To reliably detect
SIRPa expression and separate it from autofluorescence,
fluorescence minus one (FMO) control was applied, when cells
were stained for all determinants except SIRPa (9).
Quantitative RT-PCR to Determine SIRPa
mRNA Expression
RNA was isolated from FACS sorted mouse B1a and B2 cells based
on markers listed above with QIAamp RNA Blood mini kit
according to manufacturer’s instructions (Qiagen, Venlo, The
Netherlands). RNA was eluted with 30 ml H2O, to obtain as high
as possible concentration of RNA. Total RNA was reverse
transcribed using the III first-strand synthesis system for RT-PCR
(Invitrogen, Breda, The Netherlands). In short, 8-µl RNA was
primed with 2.5 µM oligo-dT primer which specifically targets
mRNA and 0.5 mM dNTP for 5 min at 65°C. Reverse transcription
was performed with 10 U/µl Superscript III in the presence of 5 mM
MgCl2, 20mMTris-HCL, and 50mMKCl, pH 8.4 (RT buffer), 2 U/
µl RNAseOUT™, lacking DTT for reasons described before (29) for
50 min at 50°C. After that, Superscript III was inactivated by
incubation for 5 min at 85°C, followed by chilling on ice.Frontiers in Immunology | www.frontiersin.org 3Immediately thereafter, 2 U RNase H was added and incubated at
37°C for 20 min. Subsequently cDNA was stored at −20°C until
further use. Amplification by PCR was performed on a LightCycler
instrument (Roche, Almere, The Netherlands), with software
version 3.5. The reaction was performed with Lightcycler
FastStart DNA MasterPLUS SYBR Green I (Roche, Almere, The
Netherlands). The annealing temperature used for all primers was
60°C. The reaction mix consisted of 4 µl of cDNA, 1 µM of each
primer combination and 4 µl of Lightcycler FastStart DNA
MasterPLUS SYBR Green I (Roche) in a total volume of 20 µl.
After an incubation step for 10 min at 95°C, the template was
amplified for 45 cycles at 95°C, annealing of the primers was
performed at 60°C for 30 s, followed by extension at 72°C for 15
s. At the end of the 45 cycles, a melting curve was generated to
determine the unique features of the DNA amplified. cDNA of
control wt animals was used as a standard curve with a serial 10-fold
dilution. Musculus Ubiquitin C was used as a reference gene. The
product was sequenced by Big-dye Terminator Sequencing and ABI
Prism software (Applied Biosystems, Foster City, USA). The
sequence obtained was verified with BLAST (http://www.ncbi.
nlm.nih.gov/BLAST/) to determine specificity. Primer sequences
are available upon request.
Binding of Phosphatidylcholine by Primary
Mouse B Cells
B cells were isolated and labeled with antibodies against surface CD5
and B220 as described above along with fluorescein-labeled
phosphatidylcholine (PtC) liposomes (DOPC/CHOL 55:45,
Formumax Scientific Inc.). The cells were incubated on ice for
20 min followed by two washing steps, then cells were analyzed
using an LSRII flow cytometer (BD Biosciences, Bedford,MA, USA)
for binding of phosphatidylcholine and data were processed with
FlowJo software (FlowJo LLC, Ashland, OR, USA).
Intracellular Calcium Mobilization
Measurement in Primary Mouse B1a Cells
B cells were isolated from the peritoneal cavity of 8–12 weeks old
SIRPaDCYT mice and aged matched wt mice using peritoneal
lavage as described above. First, Fc receptors were blocked using
a-CD16/CD32 antibody (clone 2.4G2, BD Biosciences, Bedford,
MA, USA). The cells were then stained with directly labeled
antibody against CD5 (APC) and B220 (APC Cy7, both BD
Biosciences, Bedford, MA, USA) allowing identification of B1a
cells. Calcium flux was determined as described before by flow
cytometric determination (30). Briefly, intracellular fluxes of
Ca2+ were measured using Fluo-3-AM and Fura Red-AM
fluorogenic probes (Life Technologies, Carlsbad, CA, USA).
The cells were incubated with 5m Fluo3-AM and 5mM Fura
Red-AM in loading buffer (Hank’s balanced salt solution
medium supplemented with 10 mM HEPES and 5% fetal calf
serum) at 30°C for 30 min in the dark. Cells were then washed
and resuspended in buffer (Hank’s balanced salt solution
medium with 10 mM HEPES, 5% fetal calf serum and 1mM
CaCl2) at room temperature. Cells were warmed to 37 °C for
5 min before acquisition of events. BCR-mediated Ca2+
mobilization was measured for 60s after the cells wereOctober 2020 | Volume 11 | Article 570963
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mouse IgM (Jackson ImmunoResearch, West Grove, PA, USA)
or 0.5mM phosphatidylcholine (PtC) (F60103F-F, FormuMax
USA). At the end of each Ca2+ measurement, cells were treated
with ionomycine (Life Technologies, Eugene, OR, USA) as a
positive control for calcium signaling. Data were acquired on an
LSRII flow cytometer (BD Biosciences, Bedford, MA, USA) and
data analysis was performed with the use of FlowJo software
(FlowJo LLC, Ashland, OR, USA).
Immunization of Mice With DNP-Ficoll
For B1-specific immunization intraperitoneal injection of TI-2
antigen di-nitro phenyl (DNP)-Ficoll was used as described
originally in (31). Briefly, mice were injected with 50 mg of
DNP-Ficoll in 200-ml PBS solution or with 200 ml of PBS only as
control. After 7 days animals were sacrificed and their blood was
collected, plasma was harvested and stored at −80°C before
analysis of IgM and IgG3 antibodies by ELISA.
Measurement of IgM and IgG With ELISA
Plasma levels of IgM antibodies against several OSE were
determined by chemiluminescent ELISA (32). Dilutions of 1:100
[anti-phosphocholine (PC)-BSA IgM and all IgG antibodies], 1:500
[E06/T15id+ IgM, anti-malondialdehyde (MDA-)LDL IgM, anti-
Cu-OxLDL IgM], and 1:20.000 (total IgM) were used. Supernatants
of peritoneal B1 cell cultures or plasma of mice were serially diluted
to determine IgM production after 48 h of stimulation or IgM/IgG3
against DNP-Ficoll after 7-days immunization as previously
described (33). Briefly, supernatants were measured by sandwich
ELISA, using unlabeled for coating and peroxidase‐labeled anti‐
mouse IgM/IgG antibody (total, or DNP-Ficoll specific, Southern
Biotechnology, Birmingham, AL, USA) for detection, and azino‐bis‐
ethylbenz‐thiazoline sulfonic acid was used as the substrate.
Antibody concentrations were calculated by using purified mouse
IgM protein (IgM DNP-Ficoll and IgG3 DNP-Ficoll PMP52,
Serotec, UK) as a standard.
Proliferation of B1 Cells
B cells were isolated from the peritoneal cavity of either wt or
SIRPaDCYT mice and either left unstimulated or incubated with
various stimuli for 48h after labeling with CFSE dye. Dilution of
the dye after cell division was determined by flow cytometry on
B1a cells (gated for CD19+, CD5+, CD11b+ lymphocytes) and
percentage of proliferating cells was calculated.
Stimulation of Peritoneal B1 Cell
Peritoneal B1a cells were obtained through negative magnetic-
activated cell separation with a cocktail of antibodies depleting
other than B1a cells achieving more than 90% purity in isolation
(Miltenyi Biotec B.V., Utrecht, The Netherlands). B1a cells were
subsequently counted and plated in IMDMmedium (Invitrogen,
Eugene, OR, USA) supplemented with 10% fetal calf-serum
(FCS; Bodinco, Alkmaar, The Netherlands, 100 U/ml of
penicillin, 100 mg/ml of streptomycin, and 2 mM L-glutamine
(all Gibco Invitrogen, Breda, The Netherlands), and beta-
mercapthoethanol (3.57 × 10–4M; Millipore, Amsterdam, The
Netherlands). Cells were plated in 96-well plate in density of 1 ×Frontiers in Immunology | www.frontiersin.org 4106/ml in 200 ml of medium and cultured at 37°C and 5% CO2
for 48h in presence of 5 mg of lipopolysaccharide (LPS, isolated
from E. coli strain 055:B5, Sigma, St. Louis, MO, USA; LBP from
R&D Systems, Abingdon, UK), isotype control (rat IgG2b,
eBioscience, San Diego, CA, USA), anti-CD11b antibody
(functional grade, eBioscience, San Diego, CA, USA), or anti-
CD11a (functional grade, eBioscience, San Diego, CA, USA) in
final concentration 10 mg/ml. After that supernatant was
collected and stored at −80°C before measurement of IgM
antibody by ELISA. Cells were harvested and processed for
analysis by flow cytometry and imaging cytometry.
Image Stream Analysis of Aggregate
Formation
LPS-stimulated B1a cells were stained with following antibodies:
CD19 (PerCP Cy5.5), CD11b (Alexa Fluor 488), CD5 (PE),
SIRPa (APC), (all antibodies purchased from eBioscience, San
Diego, CA, USA) and analyzed imaging cytometry to detect
formation of aggregates (Image Stream, (Image Stream, Amnis,
EMD, Millipore, Seattle, WA, USA) with gating strategy as
follows: all events were divided based on their size into single
cells (1 cell); doublets (2 cells); doublets and small aggregates (2–
3 cells); big aggregates (3–4 cells); and large aggregates (>4 cells).
Analysis of data was performed using analysis software IDEAS
(Amnis Corporation, Seattle, WA, USA) and depicted as
percentage of all gated events.
Adoptive Transfer of Peritoneal B1 Cells
Either wt or SIRPaDCYT animals were used as donors of peritoneal
B1 cells for adoptive transfer. Cells were harvested by peritoneal
lavage as described above. The cells were left in IMDM medium
supplemented with 10% FCS (Bodinco, Alkmaar, The
Netherlands, 100 U/ml of penicillin, 100 mg/ml of streptomycin,
and 2 mM L-glutamine (all Gibco Invitrogen, Breda, The
Netherlands) to rest for 30 min. After that the easy to detach
and floating cells (excluding adherent peritoneal macrophages)
were first incubated with Fc receptor blocking antibody (anti-
CD16/CD32) and after washing incubated with either isotype
control (rat IgG2b, eBioscience, San Diego, CA, USA) or anti-
CD11b antibody (functional grade, eBioscience, San Diego, CA,
USA) in concentration of 10 mg/ml for 30 min. Antibodies were
washed away and wt and SIRPaDCYT cells were labeled with
membrane dye DiD and DiO, respectively (or vice versa, to
exclude effect of the dye on cell properties). Cells were washed
multiple times and mixed in 50:50 ratio based on a cell count. The
actual ratio was additionally determined by analyzing a small
sample of pooled cells on flow cytometer allowing later
normalization of the cell input. Cells were then injected into the
peritoneal cavity of either wt or SIRPaDCYT recipient mice, left
resting for 1 h, and followed by either 200-ml injection of PBS
(control) or 10 mg of LPS in 200-ml PBS intraperitoneally to induce
migration of B1 cells from the peritoneal cavity (7, 33). Peritoneal
lavage of recipient mice was performed 3h after PBS/LPS injection.
Lavage composition was analyzed by flow cytometry in CD19+
single cell population and percentage of cells with distinct
membrane label was calculated. Percentage of cells was
normalized for input of pooled cells as indicated above.October 2020 | Volume 11 | Article 570963
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One week before transplantation, female LDLR−/− mice were
housed in filter top cages with neomycin (100 mg/L; Gibco,
Breda, The Netherlands) and polymyxin B sulphate (66104 U/L;
Gibco Breda, The Netherlands) in their acidified drinking water.
The animals received 6 Gy of total body irradiation twice on
consecutive days. Bone marrow isolated from SIRPaDCYT and wt
micewas injected intravenously to rescue thehematopoietic system
of the irradiated mice as described previously (34). Briefly, one
week before transplantation, female LDLR−/− mice were housed
in filter-top cages and provided with acidified water containing
neomycin (100mg/l; GIBCO, Breda, The Netherlands) and
polymyxin B sulfate (6 × 104 U/l; GIBCO). The animals received
2 × 6 Gy total body irradiation on two consecutive days. On the
second day, bonemarrowwas isolated from 6 SIRPaDCYT and 6 wt
littermates, and 107 cells/mouse were injected intravenously to
rescue the hematopoietic system of the irradiatedmice. Fourweeks
after the transplantation, mice were put on a high fat diet (0.15%
cholesterol, 16% fat, Arie Blok, The Netherlands) for 10 weeks and
level of chimerism was tested (reached 98.76% ± 0.73).
Mouse Blood Parameters
Blood was withdrawn at the indicated times during high fat diet
period and plasma lipid levels were enzymatically measured
using ELISA (Sigma Aldrich, Zwijndrecht, The Netherlands).
Atherosclerotic Lession Analysis
Transplanted animals were sacrificed and isolated hearts were cut
perpendicularly to heart axis just below the atrial tips, as described
before (35, 36). Briefly, tissue was frozen in tissue-tec (Shandon,
Veldhoven, The Netherlands) with the base facing downward, and
sectioningwas performed toward the aortic valve area. Sections of 7
mm were collected, starting from where the atrioventricular valves
were visible. Aortic lesion areas were quantified using serial cross-
sections obtained every 42 mm, beginning at the start of the
atrioventricular valves and spanning 250 mm. Serial cross sections
were stained with toluidin blue and lesion areas were quantified
using Adobe Photoshop software. Severity of lesions was scored as
early,moderate andadvanced, using criteria as describedbefore (35,
36). In detail, early lesions were fatty streaks containing only foam
cells; moderate (intermediate) lesions were characterized by the
additional presence of a collagenous cap, and advanced lesions
showed involvement of the media mostly accompanied by
increased collagen content and necrosis of the plaque. Foam cell
size within plaques was determined by dividing the size
of an allocated foamy macrophage area by the number
of macrophages.
Immunohistochemical Staining
Atherosclerotic lesions from aortic roots were stained with
various antibodies to identify neutrophils (NIMP directed
against Ly6G, a gift from P. Heeringa), T cells (KT3, directed
against CD3) and newly recruited macrophages (ER-MP58, a gift
from P. Leenen) followed by detection with biotin labeled rabbit
anti-rat antibody and staining with ABC kit (Vector Labs,
Burlingame, CA).Frontiers in Immunology | www.frontiersin.org 5Statistical Analysis
Statistical analysis was performed using GraphPad Prism version
8.02 (GraphPad Software, San Diego, CA, USA). Data were
evaluated by two-tailed student t-test if two columns were
compared. If more columns were compared, one-way ANOVA
followed by multiple comparison correction was applied.RESULTS
SIRPa Is Expressed on B1 Cells
The inhibitory immunoreceptor SIRPa is considered to be present
selectively on neuronal cells as well as on myeloid cells in the
hematopoietic compartment (1, 37). It is thought to be lacking
from lymphoid cells, at least under steady state conditions (38).
However, a more detailed evaluation of B cell subsets revealed
SIRPa expression on all B1 cells in the peritoneal cavity (PC) and
on a subpopulation of B cells in the spleen (SP) of mice (Figures
1A–C and Supplementary Figures 1A, B). In particular, by using
specific markers identifying B1a cells (i.e., CD19+CD5+CD11b+)
and B1b cells (i.e., CD19+CD5−CD11b+) we could clearly
demonstrate surface SIRPa expression on both of these PC B1
lymphocyte populations. PC B2 cells show much lower if any
SIRPa expression. In the spleen we could detect expression of
SIRPa only on a subset of B220+/CD19+CD43+CD23− B1 cells.
Relatively low levels of SIRPa staining were found on marginal
zone B cells (B220+/CD19+CD43−CD23−) and minimal detectable
expression was found on B220+/CD19+CD23+CD43− follicular B
cells. Consistent with other studies (38), we could not observe any
SIRPa expression on circulating B cells in mice and no expression
on B2 cells from the bone marrow (Supplementary Figure 1C).
However, we could detect SIRPa on fetal liver B220+/CD19+CD43+
B cells and B1 cells in the bone marrow (Supplementary Figure
1C). As a control staining was performed on B1 cells from the
peritoneal cavity of mice deficient for SIRPa altogether (SIRPa−/−
mice, Supplementary Figure 2) indicating that staining observed
on B1 cells in wild type mice can indeed be solely attributed
to SIRPa expression on those cells. Staining on B1 cells from
SIRPaDCYT mice showed a slightly reduced overall surface
expression as has been reported for other cells expressing SIRPa
(data not shown). Compared with peritoneal macrophages, we
found substantially lower levels of both CD11b and SIRPa on B1
cells, clearly discriminating B1 cells frommyeloid cells (Figure 1D).
Expression of SIRPamRNA was confirmed by qRT-PCR on FACS
sorted peritoneal B1a cells (CD19+CD5+CD11b+) (Figure 1E).
SIRPa Limits Natural IgM Antibody Levels
In Vivo
Because SIRPa, like Siglec-G, is also a typical inhibitory
immunoreceptor with cytoplasmic ITIM motifs signaling through
SHP-1 and/or SHP-2, we tested whether the lack of SIRPa signaling
would affect natural antibody generation as well. As can be seen in
Figure 2A there was a prominent (~2-fold) enhancement in the
plasma levels of total and OSE-reactive natural IgM antibodies in
mice lacking the cytoplasmic tail of SIRPa (SIRPaDCYT mice). This
occurred for all OSE tested, including the so-called T15 epitope thatOctober 2020 | Volume 11 | Article 570963
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anti-atherogenic potential in vivo (11, 39), as well as phosphocholine
(PC) and those against ex vivo oxidized LDL (i.e., MDA-LDL and
Cu-OxLDL). Consistent with a specific B1 cell phenotype and a
selective regulation of natural IgM levels the corresponding IgG
levels were not altered (Figure 2B). When SIRPaDCYT mice were
immunized with a typical T-cell independent type 2 (TI-2) antigen,
DNP-Ficoll, we observed robust and enhanced DNP-specific IgM
and IgG3 immune responses (Figure 2C). Of interest, no enhanced
antibody responses have been observed in SIRPaDCYT mice upon
immunization with the thymus-dependent antigen TNP-KLH (Y.
Kaneko (Gunma University, Japan), personal communication).
These results indicate that SIRPa signaling regulates natural
antibody production as well as the response of B1 cells to
antigenic stimulation.
SIRPa Increases Splenic B1 Cell Numbers
Without Affecting B Cell Receptor
Function
Next, we investigated whether the changes in B1-cell associated
antibodies in SIRPaDCYT mice could be related to changes in B1
cell numbers in the peritoneal cavity or the spleen of these miceFrontiers in Immunology | www.frontiersin.org 6(Figure 2D, Supplementary Figures 3A–G). We did not detect
significant differences in proportions or the absolute numbers of
peritoneal cavity B1a and B1b cells. In contrast, proportions and
absolute numbers of B1 cells in the spleen of SIRPaDCYT mice
were significantly (~2-fold) increased compared to wt animals.
There were no significant differences in total cell numbers or
proportions of other splenic B cell subsets, indicating that the
effects were specific for B1 cells. We next asked how SIRPamight
contribute to the increase in splenic B cell numbers and natural
antibody levels. One possibility was that SIRPa was controlling
the activation and expansion of B1 cells. First, we tested whether
antigen recognition by B1 cells might be altered, as a
consequence of potential differences in BCR expression, but we
observed no difference in, e.g., the binding of a typical B1a cell
antigen phosphatidylcholine (PtC) (40) to B1a cells (Figure 3A
and Supplementary Figure 3H). Next, we explored potential
differences in B1a cell activation capacity. This included
measuring Ca2+ flux upon cross-linking of BCR (Figure 3B),
and monitoring sorted PC B1a cell IgM secretion upon
stimulation with LPS in vitro (Figure 3C), a potent and typical
B1 cell activation stimulus (7). Both read-outs showed
comparable activation capacity of wt and SIRPaDCYT B1a cells.A
B
D
E
C
FIGURE 1 | SIRPa is expressed by B1 cells. (A) Imaging flow cytometry visualizing expression of SIRPa on CD19+CD5+CD11b+ B1a cells and CD11b+CD19−
macrophages. Representative histograms (B) and synopsis (C) of SIRPa surface expression on defined B cell subpopulations as determined by flow cytometry (MFI,
Mean fluorescence intensity). Note that the most prominent expression occurs on peritoneal cavity (PC) B1a and B1b cells, and on a subset of the splenic (SP) B1,
with little or no expression on marginal zone (MZ) and follicular (FO) B cells. (D) Macrophages cells from the peritoneal cavity show relatively high levels of expression
of both CD11b and SIRPa. (E) SIRPa mRNA expression on FACS sorted peritoneal cavity B1a and B2 cells. Data are in (C, E) are presented as mean ± SEM and
represent measurements of 5–8 and 3 individual mice, respectively. Statistical analysis was performed by one-way ANOVA with Dunnett’s multiple comparison
corrrection, ****p < 0.0001.October 2020 | Volume 11 | Article 570963
Franke et al. SIRPa on Mouse B1 CellsFinally, there were apparently no differences in B1a cell
proliferation (Supplementary Figure 4). Taken together, these
findings support the idea that SIRPa signaling controls splenic
B1 cell accumulation and, likewise as a consequence, also the
levels of naturally occurring antibodies, but this was apparently
not linked to a generalized regulation of BCR- or TLR-mediated
B1 cell activation.
SIRPa Regulates CD11b/CD18 Integrin
Function and B1 Cell Migratory Capacity
Notably, when analyzing LPS-stimulated B1 cells by flow
cytometry, we observed the presence of cell clusters in the
cultures that appeared larger for SIRPaDCYT B1a cells relative
to their wt counterparts (Supplementary Figure 5A). This
prompted us to visualize and quantify this aggregate formation
of B1a cells by imaging flow cytometry, which indeed
consistently demonstrated a substantially increased proportion
of large aggregates (i.e., consisting of more than 4 cells) in
SIRPaDCYT peritoneal B1a cells as compared to wt B1a cells
after LPS stimulation (Figure 4A and Supplementary Figures
5B, C). In contrary, we could not observe comparable aggregates
when sorted splenic B1 cells were cultured in a similar manner
(Figure 4B). Interestingly, such doublets and large aggregates
specific for CD11b+ B1 cells have been previously reported by
Ghosn et al. and their formation seems to be dependent on
CD11b (9). Furthermore, SIRPa inhibitory signaling has been
previously linked to integrin function in other cells (28). WeFrontiers in Immunology | www.frontiersin.org 7therefore hypothesized that SIRPa may serve as a negative
regulator of CD11b/CD18 integrin function in B1 cells. To test
this, we stimulated sorted peritoneal B1a cells with LPS in the
presence of a blocking anti-CD11b antibody. Clearly, the
increased formation of large aggregates triggered by LPS in
mice lacking SIRPa signaling could be partially prevented by
blocking CD11b, but not by blocking CD11a (Figure 4C). Next,
we asked whether B1 cell aggregate formation through CD11b/
CD18 integrin could be a prerequisite for production of natural
antibodies. We tested supernatants of B1a cells that were
activated by LPS in the presence of blocking CD11b antibody
or blocking CD11a antibody. It appeared that SIRPaDCYT B1a
cells have comparable antibody production as wt B1 cells in vitro,
independently of CD11b or CD11a function (Figure 4D). Thus,
whereas CD11b-mediated formation of large aggregates did not
regulate natural antibody production in vitro, such B1 cell
aggregate formation, which was promoted upon disruption of
SIRPa signaling, nevertheless appeared a read-out for CD11b/
CD18 activation. This suggested that SIRPa signaling was
negatively regulating B1 cell integrin function. Of interest,
Waffarn et al. have shown, that CD11b/CD18, unlike CD11a/
CD18, is indispensable for migration of stimulated B1 cells from
cavities to secondary lymphoid tissues where they mature into
natural antibody producing plasma cells (8). This led us to
propose that SIRPa could actually regulate CD11b/CD18
function during migration of B1 cells to the secondary
lymphoid tissues, which would provide an explanation for theA B
DC
FIGURE 2 | Loss of SIRPa signaling promotes B1 cell accumulation in the spleen and natural IgM antibody formation in vivo. Defective SIRPa signaling in mice
lacking the SIRPa cytoplasmic tail (SIRPaDCYT) results in increased plasma levels of natural IgM (A) but not IgG (B) antibodies directed against the indicated
oxidation-specific epitopes under steady-state conditions; wt, wild-type mice; RLU/100 ms, Relative Luminescence per 100 ms. (C) Immunization with the
haptenated TI-2 antigen DNP-Ficoll triggers increased production of both IgM and IgG3 antibodies against DNP in SIRPaDCYT mice. Data are presented as mean ±
SEM and are representative of 9-10 (A), 8 (B), 17 (C) individual mice. (D) B cell numbers in peritoneal cavity and spleen of wt and SIRPaDCYT mice. Absolute number
of different B cell populations was determined in the peritoneal cavity and the spleen of young adult mice (8–12 weeks) under steady state conditions. For further
details see Supplementary Figures 2A–G. Statistical analysis was performed by unpaired Student t-test, corrected for multiple comparisons with Holm-Sedak
method where applicable, *p < 0.05; **p < 0.01, ***p < 0.001, ****p < 0.0001.; ns, non-significant; n.d., not detectable.October 2020 | Volume 11 | Article 570963
Franke et al. SIRPa on Mouse B1 Cellsincreased numbers of B1 cells in the spleens of SIRPaDCYT mice.
To directly test the effect of SIRPa signaling on the capacity of B1
cells to migrate from the peritoneal cavity we performed adoptive
transfer experiments. To confirm integrin-dependence, B1 cells
of both wt and SIRPaDCYT donor mice were in parallel pre-
incubated with blocking CD11b antibody, excessive amount of
the antibody was removed, and then, the cells were labeled with
unique membrane dyes, mixed in 1:1 ratio, and injected to either
wt or SIRPaDCYT recipients (Figure 4E). This set-up allowed us
to selectively monitor, in individual animals, the effect of SIRPa
and CD11b/CD18 on the migration of B1 cells from the
peritoneal cavity to the spleen. As expected, B1 cells that lack
inhibitory cytoplasmic tail of SIRPa showed increased efflux
from the peritoneal cavity (Figure 4F). The enhanced exit of
SIRPaDCYT B1 cells was fully dependent on CD11b/CD18, as it
could be completely inhibited by antibody blocking. Taken
together, our data strongly suggest that CD11b/CD18 function
in B1 cells is under negative control of SIRPa and that in absence
of SIRPa signaling B1 cells have a higher propensity to leave theFrontiers in Immunology | www.frontiersin.org 8peritoneal cavity, thereby contributing to an accumulation of B1
cells in the spleen and an enhanced systemic production of
natural antibodies.
Lack of SIRPa Signaling Protects Mice
From Atherosclerosis
In order to further establish the potential pathological/clinical
relevance of the regulation of natural IgM antibody production by
SIRPa in vivo, we decided to explore the role of SIRPa in
atherosclerosis. Natural IgM antibodies produced by B1a cells
have a well-established protective role in various diseases, and
particularly in atherosclerosis, a feature which is apparently due to
their capacity to neutralize oxLDL uptake and enhance apoptotic cell
clearance by macrophages (11–13). To directly address the role of
SIRPa in atherosclerosis in mice, we transplanted wt and
SIRPaDCYT bone marrow into atherosclerosis-prone LDLR−/−
recipient mice. This well-established atherosclerosis model
includes the replacement of peritoneal B cell populations
(including B1 cells) by the donor cells (11, 12, 21, 22, 41–43).A
B
C
FIGURE 3 | Loss of SIRPa signaling does not have a generalized effect on B1 cell activation. (A) Comparable frequency (FACS plot of representative example, left
panel; % positivity, middle panel) and magnitude (MFI, right panel) of phosphatidylcholine (PtC; a typical B1a antigen) antigen binding by wt and SIRPaDCYT peritoneal
cavity B1a cells (n = 7 mice/group). (B) Similar levels of B1a cell surface IgM signaling, as determined by intracellular Ca2+ mobilization, in wt and SIRPaDCYT
peritoneal cavity B1 cells triggered by anti-IgM antibodies; responses with ionomycin are shown as a positive control; left panels: representative examples of
Ca2+-responses in wt and SIRPaDCYT (B); right panels: average values of B1a cells from n = 3 mice/group. (C) Comparable levels of LPS-stimulated IgM production
in B1a cells isolated from SIRPaDCYT and wt mice (n = 10–11 mice/group); ns, non-significant.October 2020 | Volume 11 | Article 570963
Franke et al. SIRPa on Mouse B1 CellsMice transplanted with wt or SIRPaDCYT cells, and subjected to a
high-fat diet, showed neither differences in weight, plasma
cholesterol and triglyceride levels nor prominent changes in blood
cell composition (Supplementary Figures 6A–E). However, when
the atherosclerotic lesions of these mice were evaluated, it became
apparent that mice transplanted with SIRPaDCYT cells developed
much smaller lesions (Figure 5A) with a substantially less severe
phenotype (Figure 5B) compared to wt chimeras. Additionally,
when the plasma of atherosclerotic mice was analyzed for the
presence of antibodies against oxLDL, in mice transplanted with
SIRPaDCYT cells elevated levels of T15/E06 IgM (Figure 5C), an
oxLDL neutralizing antibody, being particularly critical in the
protection against atherosclerosis, were found. (11, 39, 44). Similar
to the steady state situation, levels of IgG targeting OSE remained
unaltered (Supplementary Figure 6F). A more detailed evaluation
of the cellular composition of the lesions showed an increase in the
number of newly recruited ERMP58+ myeloid cells (Figure 5D),
which was associated with a significantly decreased mRNA for
CD68+ macrophages (Figure 5E) and size of the area occupied byFrontiers in Immunology | www.frontiersin.org 9foam cells in mice transplanted with SIRPaDCYT cells (Figure 5F),
consistent with the proposed mechanism of IgM-mediated
inhibition of foam cell formation (11, 16, 45). There were no
significant differences observed in numbers of other immune cells
known to be involved in pathogenesis of atherosclerosis, such as T-
lymphocytes and neutrophils (Supplementary Figures 6G, H).DISCUSSION
In this study, we provide evidence for the expression and functional
relevance of the inhibitory receptor SIRPa on B1 cells in mice. Our
results demonstrate that SIRPa is an inhibitory receptor on B1 cells
that controls the numbers of splenic B1 cells, thereby most likely
affecting systemic natural antibody levels. The increase in splenic B1
cell numbers in the absence of SIRPa signaling occursmost probably
because of the absence of an inhibitory effect of on CD11b/CD18
integrin activation, which promotes the migration of these B1 cells
from the peritoneal cavity to the spleen. We also show that a lack ofA
B D
E F
C
FIGURE 4 | Loss of SIRPa signaling promotes LPS-induced CD11b/CD18 integrin-dependent B1 cell efflux from the peritoneal cavity. (A, B) Lack of SIRPa
signaling promotes the formation of large aggregates in isolated SIRPaDCYT peritoneal cavity (A) but not splenic (B) B1a cells (n = 6–8 mice/group). (C) Enhanced
frequency of B1 cell large aggregates in SIRPaDCYT peritoneal cavity B1a cells relative to wt cells is CD11b/CD18-integrin-dependent as it is reduced by blocking
anti-CD11b, but not anti-CD11a antibodies. (D) Blockade of CD11b/CD18 or CD11a/CD18 integrins has no effect on IgM antibody production by peritoneal cavity
B1 cells upon LPS stimulation. (E) Experimental design of egress of adoptively transferred mixed SIRPaDCYT/wt B1 cells from the peritoneal cavity. (F) Evaluation of
adoptively transferred mixed SIRPaDCYT/wt B1 cells shows increased efflux of SIRPaDCYT B1 cells relative to wt from the peritoneal cavity upon LPS stimulation and
this enhanced egress is CD11b/CD18 dependent (n = 3–12 mice/group). Similar data were obtained for SIRPaDCYT recipients (not shown). Data are presented as
mean ± SEM. Statistical analysis was performed by unpaired Student t-test, corrected for multiple comparisons with Holm-Sedak method where applicable, **p <
0.01, ****p < 0.0001; ns, non-significant.October 2020 | Volume 11 | Article 570963
Franke et al. SIRPa on Mouse B1 Cellsinhibitory SIRPa signaling in atheroscleroticmice leads to selectively
elevated plasma levels of oxLDL-neutralizing natural antibodies and
propose that this directly contributes to the atheroprotective effect of
SIRPamutation. The latter is in agreement with the well-established
regulatory role of such antibodies in atherosclerosis (46).
SIRPa is one of the most abundant inhibitory receptors on
myeloid cells including neutrophils, monocytes, the majority of
tissue macrophages and CD4+ dendritic cells, affecting a variety of
cell functions in a primarily negative fashion (1, 2). SIRPa has, as yet,
not been reported to be expressed by any B cells. Recently, SIRPawas
also reported to be selectively expressed on a small subset of T
lymphocytes, i.e., exhausted CD8+ memory T cells emerging after
chronic viral infection (47). For a long time, the general assumption
has been that SIRPa is, at least among hematopoietic cells, restricted
to the myeloid lineage (37, 48). Most of the studies based the absence
of SIRPa from lymphocytes on staining of blood cells in rodents (37,
38) while other, less accessible or more obscure subpopulations of
lymphoid origin remained unexplored. We found expression of
SIRPa exclusively on B1 cells in the peritoneal cavity and on a
minor subset of B cells in the spleen. We also observed that the
population of steady-state splenic B1 cells is roughly doubled in mice
lacking SIRPa signaling. This increase in splenic B1 cells may well
explain the (also ~2-fold) higher IgM plasma levels found inFrontiers in Immunology | www.frontiersin.org 10SIRPaDCYT mice. Antigens with repetitive patterns, such as lipids
and glycolipids, including self-antigens that are generated, e.g., upon
oxidation or apoptosis can induce multivalent antigen crosslinking of
specific BCR on B1 cells and induce TI-2 responses. Due to this self-
and poly- reactivity of B1 cells, their functions have to be tightly
regulated to avoid autoimmunity. Several inhibitory receptors that
regulate various aspects of B1 cell function are already known to be
instrumental in this.We have observed that lack of SIRPa on B1 cells
has no measurable effect on calcium flux and IgM secretion, which
may suggest that Siglec-G and CD5, which have previously shown
to regulate these parameters, comprise themajor regulators of BCR
signaling in B1 cells (17). SIRPaDCYT mice have moderately
increased numbers of B1 cells only in the spleen with the
peritoneal population virtually unaltered. Also, B1-associated
antibody levels are elevated in SIRPaDCYT mice, both at baseline
and after TI-2 antigen exposure. Natural antibodies are
predominantly produced by B1 cells in secondary lymphoid
organs such as spleen (4) or specific (e.g., mediastinal) lymph
nodes (8). Egress of B1 cells residing in the body cavities
(peritoneal or pleural) into the secondary lymphoid organs has
been demonstrated to depend on the CD11b/CD18 integrin (8).
CD11b can function only in heterodimer with CD18 integrin,
forming together CD11b/CD18 (also known as CR3, Mac-1,A
B
D E FC
FIGURE 5 | Loss of SIRPa signaling protects mice from atherosclerosis. (A, B) Bone marrow chimeras carrying dysfunctional SIRPa in their hematopoietic
compartment are protected from atherosclerosis, showing (A) smaller and (B) less severe aortic lesions. (C) Atheroprotection in SIRPaDCYT>LDLR−/− chimeras is
associated with increased levels of oxLDL-targeting natural antibody T15/E06 in plasma. (D–F) Atherosclerotic lesions of SIRPaDCYT>LDLR−/− chimeras contain more
small macrophages (D), less CD68+ macrophages (E), and a smaller foam cell area (F) as compared to wt chimeras. Data are presented as mean ± SEM and are
representative of 15-17 (A, B), 18-19 (C), and 12-16 (D–F) individual mice. Statistical analysis was performed by unpaired Student t-test used per variable,
corrected for multiple comparisons with Holm-Sedak method, *p < 0.05; ***p < 0.001 or Chi-square test (B), *p < 0.05.October 2020 | Volume 11 | Article 570963
Franke et al. SIRPa on Mouse B1 CellsIntegrin alpha M, or aMb2 integrin). B1 cells are known to express
various integrin molecules, but B1 cells are the only B cells that
express CD11b/CD18 integrin and until now no direct regulator of
its function has been described. We show here that SIRPa
negatively regulates capacity of B1 cells to exit the peritoneal
cavity through CD11b/CD18 integrin, identifying this inhibitory
immunoreceptor as the first bona fide regulator of B1 migratory
function. It should be emphasized thatwe cannot formally attribute
the in vivo phenotype of the SIRPa-mutantmice toB1 cell-intrinsic
effects of SIRPa signaling, since also other cells, such as myeloid
cells, in these mice have a defect in SIRPa signaling as well. Taken
together, a picture emerges where different B1 cell functions appear
to be regulated by distinct inhibitory receptors, with SIRPamore or
less specifically controlling their migratory behavior, whereas
others, e.g., Siglec-G and CD5 may control B1 cell activation in a
more generalized fashion.
The homeostatic function of IgM antibodies has been well
documented in atherosclerosis (11–13, 49). Mice lacking SIRPa
signaling in the hematopoietic compartment showed increased
plasma levels of T15/E06 IgM and show smaller and less severe
atherosclerotic lesions. This is consistent with observations in Siglec
G−/−bonemarrowchimeras,where the lackof inhibitory signalingby
SiglecG led to increasedOSE-specificnatural IgMantibody levels and
decreased atherosclerosis development (24). Increased plasma level
of T15/E06 IgM is a very likely mechanism of atheroprotection in
SIRPaDCYT chimeras. However, transplantation of SIRPaDCYT and
wt bone marrow resulted in replacement of both myeloid and
lymphoid lineage in the donor LDLR−/− mice. As macrophages are
important players in development of atherosclerosis we cannot
exclude their contribution to the observed phenotype, especially
since the SIRPa counter-receptor CD47 appears involved in
pathogenesis of atherosclerosis through inhibition, e.g.,
macrophage efferocytosis (50). Furthermore, whether blocking
antibodies targeting SIRPa, rather than CD47, would show similar
effect still remains to be confirmed, also because the CD47
monoclonal antibody miap410 used in the study of Kojima (50)
has prominent opsonizing capacity and a less convincing ability to
actually block the CD47-SIRPa axis (51).
Importantly, it is well established that humans, like mice, have
“natural” antibodies targeting, e.g., OSE, which are atheroprotective,
and these even appear to have prognostic value for the development
of cardiovascular disease (52). Based on our current findings in mice,
the prediction would therefore be that the human natural antibody
producing B cells would also express SIRPa and would consequently
also be subject to regulation via the CD47-SIRPa axis. The problem
is, however, that the B1 cell equivalent subset responsible for natural
antibody production in humans has not been properly identified,
and this is in fact a heavily debated issue in the B1 cell field. For
instance, the reported identification of human B1 cells in blood
defined as CD20+CD27+CD43+CD70− (53) is quite controversial
and has been challenged by several other studies suggesting that
these cells are rather result of a technical artefact (54–56). Further
studies are clearly needed to resolve this issue and to establish SIRPa
expression and function on these putative human B1 cells.
Collectively, our data identify SIRPa as a novel B1 cell immune
checkpoint, which functions to control B1 cell migration to
lymphoid tissues and natural antibody generation. Our findingsFrontiers in Immunology | www.frontiersin.org 11also imply SIRPa as a potential therapeutic target in atherosclerosis.
The CD47-SIRPa innate immune checkpoint is currently
extensively studied in the context of cancer immunotherapy (2,
57), with a number of different agents in preclinical and/or clinical
development, and ~35 ongoing clinical trials, carving out a path for
potential therapeutic targeting of the CD47-SIRPa axis also in other
diseases, including cardiovascular disease.AUTHOR’S NOTE
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